48,830
edits
Difference between revisions of "ALK translocation renal cell carcinoma"
Jump to navigation
Jump to search
ALK translocation renal cell carcinoma (view source)
Revision as of 14:09, 4 April 2019
, 14:09, 4 April 2019no edit summary
| Line 4: | Line 4: | ||
*Extremely rare - 1 in 829 consecutively screened patients.<ref name=pmid24255633>{{Cite journal | last1 = Lee | first1 = C. | last2 = Park | first2 = JW. | last3 = Suh | first3 = JH. | last4 = Nam | first4 = KH. | last5 = Moon | first5 = KC. | title = ALK-Positive Renal Cell Carcinoma in a Large Series of Consecutively Resected Korean Renal Cell Carcinoma Patients. | journal = Korean J Pathol | volume = 47 | issue = 5 | pages = 452-7 | month = Oct | year = 2013 | doi = 10.4132/KoreanJPathol.2013.47.5.452 | PMID = 24255633 }}</ref> | *Extremely rare - 1 in 829 consecutively screened patients.<ref name=pmid24255633>{{Cite journal | last1 = Lee | first1 = C. | last2 = Park | first2 = JW. | last3 = Suh | first3 = JH. | last4 = Nam | first4 = KH. | last5 = Moon | first5 = KC. | title = ALK-Positive Renal Cell Carcinoma in a Large Series of Consecutively Resected Korean Renal Cell Carcinoma Patients. | journal = Korean J Pathol | volume = 47 | issue = 5 | pages = 452-7 | month = Oct | year = 2013 | doi = 10.4132/KoreanJPathol.2013.47.5.452 | PMID = 24255633 }}</ref> | ||
*May be related to ''[[renal medullary carcinoma]]'' which is reported to have an ALK rearrangement - t(2;10)(p23;q22).<ref name=pmid21213368>{{Cite journal | last1 = Mariño-Enríquez | first1 = A. | last2 = Ou | first2 = WB. | last3 = Weldon | first3 = CB. | last4 = Fletcher | first4 = JA. | last5 = Pérez-Atayde | first5 = AR. | title = ALK rearrangement in sickle cell trait-associated renal medullary carcinoma. | journal = Genes Chromosomes Cancer | volume = 50 | issue = 3 | pages = 146-53 | month = Mar | year = 2011 | doi = 10.1002/gcc.20839 | PMID = 21213368 }}</ref> | *May be related to ''[[renal medullary carcinoma]]'' which is reported to have an ALK rearrangement - t(2;10)(p23;q22).<ref name=pmid21213368>{{Cite journal | last1 = Mariño-Enríquez | first1 = A. | last2 = Ou | first2 = WB. | last3 = Weldon | first3 = CB. | last4 = Fletcher | first4 = JA. | last5 = Pérez-Atayde | first5 = AR. | title = ALK rearrangement in sickle cell trait-associated renal medullary carcinoma. | journal = Genes Chromosomes Cancer | volume = 50 | issue = 3 | pages = 146-53 | month = Mar | year = 2011 | doi = 10.1002/gcc.20839 | PMID = 21213368 }}</ref> | ||
*May respond to [[ALK inhibitors]] | *May respond to [[ALK inhibitors]] such as alectinib<ref name=pmid29685646>{{Cite journal | last1 = Pal | first1 = SK. | last2 = Bergerot | first2 = P. | last3 = Dizman | first3 = N. | last4 = Bergerot | first4 = C. | last5 = Adashek | first5 = J. | last6 = Madison | first6 = R. | last7 = Chung | first7 = JH. | last8 = Ali | first8 = SM. | last9 = Jones | first9 = JO. | title = Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. | journal = Eur Urol | volume = 74 | issue = 1 | pages = 124-128 | month = 07 | year = 2018 | doi = 10.1016/j.eururo.2018.03.032 | PMID = 29685646 }}</ref> or crizotinib.<ref name=pmid27554841>{{Cite journal | last1 = Jeanneau | first1 = M. | last2 = Gregoire | first2 = V. | last3 = Desplechain | first3 = C. | last4 = Escande | first4 = F. | last5 = Tica | first5 = DP. | last6 = Aubert | first6 = S. | last7 = Leroy | first7 = X. | title = ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult. | journal = Pathol Res Pract | volume = 212 | issue = 11 | pages = 1064-1066 | month = Nov | year = 2016 | doi = 10.1016/j.prp.2016.07.015 | PMID = 27554841 }}</ref> | ||
==Microscopic== | ==Microscopic== | ||